DRUG
Retatrutide
Administered SC
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
Status
Completed
Phase
Phase 3
Enrollment
445
Locations
49
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks.
Interventions
Treatment arms and agents.
DRUG
Placebo
Administered SC
Timeline
From registration to results.
First posted
Jul 5, 2023
Study start
Aug 1, 2023
Primary completion
Nov 14, 2025
Study completion
Nov 14, 2025
Results posted
Not reported
Registry updated
Jan 21, 2026
Outcomes
What the study measures.
Primary outcomes
Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score
Time frame · Baseline, Week 68
Percent Change from Baseline in Body Weight
Time frame · Baseline, Week 68
Secondary outcomes
Change from Baseline in the WOMAC Physical Function Subscale Score
Time frame · Baseline, Week 68
Change from Baseline in Waist Circumference
Time frame · Baseline, Week 68
Percent Change from Baseline in Total Cholesterol
Time frame · Baseline, Week 68
Percent Change from Baseline in Triglycerides
Time frame · Baseline, Week 68
Change from Baseline in Body Mass Index (BMI)
Time frame · Baseline, Week 68
Change from Baseline in Systolic Blood Pressure (SBP)
Time frame · Baseline, Week 68
Change from Baseline in Diastolic Blood Pressure (DBP)
Time frame · Baseline, Week 68
Percent Change from Baseline in Fasting Insulin
Time frame · Baseline, Week 68
Change from Baseline in Short Form 36-Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score
Time frame · Baseline, Week 68
Change from Baseline in Average Pain Intensity Numeric Rating Score (API-NRS) Score
Time frame · Baseline, Week 68
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Have a body mass index (BMI) ≥27 kilogram/kg/m² at screening. * Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight. * Have index knee pain for \>12 weeks prior to screening, and presence of index knee pain for \>15 days over the previous month. * Have knee X-ray with moderate radiographic changes (Kellgren-Lawrence Grade 2 or 3) per central reading at screening. * Currently meets American College of Rheumatology (ACR) Criteria (clinical and radiological) for OA. Exclusion Criteria: * Have had steroid joint injections within 90 days of screening. * Have had other joint injections and procedures within 6 months of screening. * Have joint disease other than osteoarthritis. * Have a self-reported or documented change in body weight \>5 kg (11 pounds) within 90 days prior to screening. * Have been taking weight loss drugs, including over-the-counter medications, within 90 days prior to screening. * Have a prior or planned surgical treatment for obesity. * Have diabetes mellitus.
Study locations
49 registered sites.
Australia · Canada · Mexico · Spain · United Kingdom · United States. Showing up to 24 locations stored in the fast local snapshot.
Arizona Research Center
Phoenix, Arizona, United States
Artemis Institute for Clinical Research
San Diego, California, United States
Chase Medical Research, LLC
Waterbury, Connecticut, United States
Suncoast Research Group
Miami, Florida, United States
North Georgia Clinical Research
Woodstock, Georgia, United States
Elite Clinical Trials
Blackfoot, Idaho, United States
Northwestern University
Chicago, Illinois, United States
MedVadis Research Corporation
Waltham, Massachusetts, United States
Great Lakes Research Group, Inc.
Bay City, Michigan, United States
Clinvest Research LLC
Springfield, Missouri, United States
Mercy Family Clinic
Dallas, Texas, United States
Clinical Trials of Texas, Inc.
San Antonio, Texas, United States
Northwest Clinical Research Center
Bellevue, Washington, United States
Paratus Clinical Research Canberra
Bruce, Australian Capital Territory, Australia
Paratus Clinical Research Western Sydney
Blacktown, New South Wales, Australia
Emeritus Research
Botany, New South Wales, Australia
Royal Brisbane and Women's Hospital
Brisbane, Queensland, Australia
Core Research Group
Brisbane, Queensland, Australia
CDH Research Institute
Maroochydore, Queensland, Australia
Emeritus Research
Camberwell, Victoria, Australia
Barwon Health
Geelong, Victoria, Australia
C-health Research
Calgary, Alberta, Canada
Eastern Health - General Hospital
St. John's, Newfoundland and Labrador, Canada
Viable Clinical Research
Bridgewater, Nova Scotia, Canada
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Retatrutide.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Eli Lilly · Obesity · Cardiovascular Diseases
Phase 3
Completed
1,946
2026-07
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Eli Lilly · Type 2 Diabetes · Obesity
Phase 3
Completed
1,152
2026-07
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Eli Lilly · Obesity · Overweight
Phase 3
Active, not recruiting
586
2026-07
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Eli Lilly · Type 2 Diabetes
Phase 3
Active, not recruiting
320
2026-07
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly · Atherosclerotic Cardiovascular Disease (ASCVD) · Chronic Kidney Disease (CKD)
Phase 3
Active, not recruiting
10,000
2026-07
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Eli Lilly · Obesity
Phase 3
Active, not recruiting
800
2026-07
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Eli Lilly · Metabolic Dysfunction-Associated Steatotic Liver Disease
Phase 3
Recruiting
4,500
2026-07
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
Eli Lilly · Diabetes Mellitus · Insulin Sensitivity
Phase 1
Active, not recruiting
95
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.